These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 24900213)
1. Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists. Jin J; Morales-Ramos A; Eidam P; Mecom J; Li Y; Brooks C; Hilfiker M; Zhang D; Wang N; Shi D; Tseng PS; Wheless K; Budzik B; Evans K; Jaworski JP; Jugus J; Leon L; Wu C; Pullen M; Karamshi B; Rao P; Ward E; Laping N; Evans C; Leach C; Holt D; Su X; Morrow D; Fries H; Thorneloe K; Edwards R ACS Med Chem Lett; 2010 Oct; 1(7):316-20. PubMed ID: 24900213 [TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists. Morales-Ramos ÁI; Li YH; Hilfiker M; Mecom JS; Eidam P; Shi D; Tseng PS; Brooks C; Zhang D; Wang N; Jaworski JP; Morrow D; Fries H; Edwards R; Jin J Bioorg Med Chem Lett; 2011 May; 21(10):2806-11. PubMed ID: 21514150 [TBL] [Abstract][Full Text] [Related]
3. Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists. Budzik B; Garzya V; Shi D; Walker G; Woolley-Roberts M; Pardoe J; Lucas A; Tehan B; Rivero RA; Langmead CJ; Watson J; Wu Z; Forbes IT; Jin J ACS Med Chem Lett; 2010 Sep; 1(6):244-8. PubMed ID: 24900202 [TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists. Zhu B; Zhang X; Guo L; Rankin M; Bakaj I; Ho G; Lee SP; Norquay L; Macielag M ACS Med Chem Lett; 2022 Jan; 13(1):111-117. PubMed ID: 35059130 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes. Zhang X; Zhu B; Guo L; Bakaj I; Rankin M; Ho G; Kauffman J; Lee SP; Norquay L; Macielag MJ ACS Med Chem Lett; 2021 Mar; 12(3):451-458. PubMed ID: 33738072 [TBL] [Abstract][Full Text] [Related]
6. Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists. Yang C; Balsells J; Chu HD; Cox JM; Crespo A; Ma X; Contino L; Brown P; Gao S; Zamlynny B; Wiltsie J; Clemas J; Lisnock J; Gibson J; Zhou G; Garcia-Calvo M; Bateman TJ; Tong V; Xu L; Crook M; Sinclair P; Shen HC ACS Med Chem Lett; 2015 Apr; 6(4):461-5. PubMed ID: 25941555 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778 [TBL] [Abstract][Full Text] [Related]
8. 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists. Li YH; Tseng PS; Evans KA; Jaworski JP; Morrow DM; Fries HE; Wu CW; Edwards RM; Jin J Bioorg Med Chem Lett; 2010 Nov; 20(22):6744-7. PubMed ID: 20926294 [TBL] [Abstract][Full Text] [Related]
9. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery. Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217 [TBL] [Abstract][Full Text] [Related]
10. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. Sakauchi N; Kohara Y; Sato A; Suzaki T; Imai Y; Okabe Y; Imai S; Saikawa R; Nagabukuro H; Kuno H; Fujita H; Kamo I; Yoshida M J Med Chem; 2016 Apr; 59(7):2989-3002. PubMed ID: 26954848 [TBL] [Abstract][Full Text] [Related]
11. Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity. Schenkel LB; Olivieri PR; Boezio AA; Deak HL; Emkey R; Graceffa RF; Gunaydin H; Guzman-Perez A; Lee JH; Teffera Y; Wang W; Youngblood BD; Yu VL; Zhang M; Gavva NR; Lehto SG; Geuns-Meyer S J Med Chem; 2016 Mar; 59(6):2794-809. PubMed ID: 26942860 [TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Engers JL; Bollinger KA; Weiner RL; Rodriguez AL; Long MF; Breiner MM; Chang S; Bollinger SR; Bubser M; Jones CK; Morrison RD; Bridges TM; Blobaum AL; Niswender CM; Conn PJ; Emmitte KA; Lindsley CW ACS Med Chem Lett; 2017 Sep; 8(9):925-930. PubMed ID: 28947938 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel xanthine derivatives as potent and selective A Basu S; Barawkar DA; Ramdas V; Patel M; Waman Y; Panmand A; Kumar S; Thorat S; Naykodi M; Goswami A; Reddy BS; Prasad V; Chaturvedi S; Quraishi A; Menon S; Paliwal S; Kulkarni A; Karande V; Ghosh I; Mustafa S; De S; Jain V; Banerjee ER; Rouduri SR; Palle VP; Chugh A; Mookhtiar KA Eur J Med Chem; 2017 Jul; 134():218-229. PubMed ID: 28415011 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of a potent, well-balanced EP Kinoshita A; Higashino M; Yoshida K; Aratani Y; Kakuuchi A; Hanada K; Takeda H; Naganawa A; Matsuya H; Ohmoto K Bioorg Med Chem; 2018 Jan; 26(1):200-214. PubMed ID: 29203142 [TBL] [Abstract][Full Text] [Related]
15. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. part 2: optimization of the side chains to improve in vitro and in vivo potencies. Asada M; Iwahashi M; Obitsu T; Kinoshita A; Nakai Y; Onoda T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M Bioorg Med Chem; 2010 Feb; 18(4):1641-58. PubMed ID: 20129791 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists. Nirogi R; Shinde A; Daulatabad A; Kambhampati R; Gudla P; Shaik M; Gampa M; Balasubramaniam S; Gangadasari P; Reballi V; Badange R; Bojja K; Subramanian R; Bhyrapuneni G; Muddana N; Jayarajan P J Med Chem; 2012 Nov; 55(21):9255-69. PubMed ID: 23006002 [TBL] [Abstract][Full Text] [Related]
17. Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. Michaelides MR; Kluge A; Patane M; Van Drie JH; Wang C; Hansen TM; Risi RM; Mantei R; Hertel C; Karukurichi K; Nesterov A; McElligott D; de Vries P; Langston JW; Cole PA; Marmorstein R; Liu H; Lasko L; Bromberg KD; Lai A; Kesicki EA ACS Med Chem Lett; 2018 Jan; 9(1):28-33. PubMed ID: 29348807 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors. Qin D; Lin X; Liu Z; Chen Y; Zhang Z; Wu C; Liu L; Pan Y; Laquerre S; Emery J; Fergusson J; Roland K; Keenan R; Oliff A; Kumar S; Cheung M; Su DS ACS Med Chem Lett; 2021 Jun; 12(6):1005-1010. PubMed ID: 34141085 [TBL] [Abstract][Full Text] [Related]
19. Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis. Pernomian L; da Silva CHTP Eur J Pharmacol; 2015 Oct; 764():118-123. PubMed ID: 26142084 [TBL] [Abstract][Full Text] [Related]
20. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]